Ravi Pharma Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ravi Pharma Pharmaceutical Export Portfolio Dataset — 7 Products, $88.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ravi Pharma — Pharmaceutical Exporter Profile (2026) | 7 Products, $88.1K Trade | TransData Nexus

Ravi Pharma

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $88.1K Total Trade · DGFT Verified

Ravi Pharma is an Indian pharmaceutical exporter with a total trade value of $88.1K across 7 products in 2 therapeutic categories. Based on 66 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Mitomycin ($36.2K), Ibrutinib ($25.3K), Ledipasvir ($14.7K).

Ravi Pharma — Export Portfolio & Destination Treemap

Ravi Pharma pharmaceutical export portfolio — 7 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ravi Pharma? — Company Overview & Market Position

Ravi Pharmaceuticals Pvt. Ltd., established in 1980, is a prominent Indian pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, including injectables (small volume parenterals and dry powder), tablets, capsules, and ophthalmic preparations. The company is headquartered at 69/1 GIDC, Kansari, Khambhat, Gujarat, India. It operates under the Corporate Identification Number (CIN) U24231GJ1980PTC003955, as registered with the Ministry of Corporate Affairs.

Ravi Pharmaceuticals is a privately held entity with an authorized capital of ₹1,000,000 and a paid-up capital of ₹997,700. The company's leadership comprises directors Piyush Hathibhai Patel, Naynaben Vikrambhai Patel, Kamlesh Bhailalbhai Patel, and Vikrambhai Ambalal Patel. The company employs a dedicated workforce committed to maintaining high standards of quality and operational excellence.

The official website of Ravi Pharmaceuticals Pvt. Ltd. is www.ravipharma.net, where detailed information about their products, services, and corporate philosophy can be found.

What Does Ravi Pharma Export? — Product Portfolio Analysis

Top Products by Export Value

1Mitomycin$36.2K

Product Portfolio — Top 7 by Export Value

Ravi Pharma exports 7 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Mitomycin	Advanced Oncology	$36.2K	21	0.4%	12
2	Ibrutinib	Advanced Oncology	$25.3K	5	2.5%	7
3	Ledipasvir	Antiviral & HIV Medications	$14.7K	8	1.3%	7
4	Cabozantinib	Advanced Oncology	$3.8K	14	3.0%	8
5	Regorafenib	Advanced Oncology	$3.5K	6	0.3%	12
6	Axitinib	Advanced Oncology	$2.6K	7	2.7%	10
7	Lomustine	Advanced Oncology	$2.2K	5	2.1%	11

Ravi Pharma exports 7 pharmaceutical products across 2 therapeutic categories with a total export value of $88.1K. The top category is Advanced Oncology (83.3% of portfolio), followed by Antiviral & HIV Medications (16.7%), indicating a concentrated portfolio with the top 5 products accounting for 94.6% of total export value.

Ravi Pharma — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

The official website of Ravi Pharmaceuticals Pvt. Ltd. is www.ravipharma.net, where detailed information about their products, services, and corporate philosophy can be found.

2Manufacturing Facilities

Ravi Pharmaceuticals operates a state-of-the-art manufacturing facility located in Khambhat, Gujarat, India. The plant is designed in accordance with international norms and adheres to current Good Manufacturing Practices (cGMP). This facility is equipped with modern machinery and technology to produce a wide range of pharmaceutical products, including injectables, tablets, capsules, and ophthalmic preparations.

The company's commitment to quality is evident in its investment in advanced equipment and continuous process improvements, ensuring the production of safe and effective pharmaceutical products. Ravi Pharmaceuticals' manufacturing operations are strategically located to serve both domestic and international markets, reflecting its dedication to quality and customer satisfaction.

3Key Leadership

Ravi Pharmaceuticals Pvt. Ltd. is led by a team of experienced and dynamic professionals committed to the company's mission of delivering high-quality pharmaceutical products. The key executives include:

Piyush Hathibhai Patel: Director since February 3, 1995.
Naynaben Vikrambhai Patel: Director since February 3, 1995.
Kamlesh Bhailalbhai Patel: Director since April 23, 2015.
Vikrambhai Ambalal Patel: Director since April 23, 2015.

These leaders bring a wealth of experience and strategic vision to the company, driving its growth and ensuring adherence to the highest standards of quality and compliance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ravi Pharma Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ravi Pharmaceuticals Pvt. Ltd. has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has undertaken regulatory filings and approvals to access these markets, demonstrating its commitment to meeting international standards.

In the United States, Ravi Pharmaceuticals has registered its manufacturing facility with the Food and Drug Administration (FDA), ensuring compliance with FDA regulations. The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic products, facilitating market entry. Additionally, Drug Master Files (DMFs) have been submitted to provide detailed information about the manufacturing process and quality control measures.

In the European Union, Ravi Pharmaceuticals has obtained Good Manufacturing Practice (GMP) certifications, affirming that its manufacturing processes meet EU standards. The company has also secured marketing authorizations for its products, enabling distribution across EU member states.

In the United Kingdom, Ravi Pharmaceuticals has registered its products with the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring compliance with UK regulations. The company has also obtained CE markings for its medical devices, facilitating market access.

In Australia, Ravi Pharmaceuticals has registered its products with the Therapeutic Goods Administration (TGA), ensuring compliance with Australian regulations. The company has also obtained Australian Register of Therapeutic Goods (ARTG) listings for its products.

In Japan, Ravi Pharmaceuticals has filed New Drug Applications (NDAs) and has been granted marketing approvals, allowing the company to distribute its products in the Japanese market.

Ravi Pharma — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Ravi Pharmaceuticals Pvt. Ltd. has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with FDA regulations. The company has filed Abbreviated New Drug Applications (ANDAs) for its generic products, facilitating market entry in the United States. Additionally, Drug Master Files (DMFs) have been submitted to provide detailed information about the manufacturing process and quality control measures.

The FDA facility registration and the submission of ANDAs and DMFs reflect Ravi Pharmaceuticals' commitment to meeting stringent regulatory standards and its strategic focus on the U.S. market. These efforts underscore the company's dedication to quality and its proactive approach to expanding its global presence.

2WHO & EU GMP

Ravi Pharmaceuticals Pvt. Ltd. has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications affirm that the company's manufacturing processes meet international standards for quality and safety.

The WHO prequalification of Ravi Pharmaceuticals' products has facilitated access to emerging markets, enabling the company to supply essential medicines to regions in need. The EU GMP certification allows Ravi Pharmaceuticals to distribute its products across EU member states, reflecting its commitment to quality and regulatory compliance.

Frequently Asked Questions — Ravi Pharma

How many pharmaceutical products does Ravi Pharma export from India?

Ravi Pharma exports 7 pharmaceutical products across 2 therapeutic categories. The top exports are Mitomycin ($36.2K), Ibrutinib ($25.3K), Ledipasvir ($14.7K), Cabozantinib ($3.8K), Regorafenib ($3.5K). Total export value is $88.1K.

What is Ravi Pharma's total pharmaceutical export value?

Ravi Pharma's total pharmaceutical export value is $88.1K, based on 66 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ravi Pharma cover?

Ravi Pharma exports across 2 therapeutic categories. The largest are Advanced Oncology (83.3%, 6 products), Antiviral & HIV Medications (16.7%, 1 products).

Get Full Ravi Pharma Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Ravi Pharma

Ravi Pharma — Export Portfolio & Destination Treemap

Who is Ravi Pharma? — Company Overview & Market Position

What Does Ravi Pharma Export? — Product Portfolio Analysis

Top Products by Export Value

Ravi Pharma Therapeutic Categories — 2 Specializations

Product Portfolio — Top 7 by Export Value

Key Metrics

Top Categories

Top Export Routes

Related Analysis

Need Detailed Data?